disitamab vedotin + fruquintinib + tislelizumab

This is a combination regimen of three anticancer agents with distinct mechanisms of action, used in investigational settings for the treatment of advanced solid tumors, particularly HER2-expressing cancers and urothelial carcinoma. Disitamab vedotin is an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2), consisting of a humanized monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE) via a cleavable linker. Fruquintinib is an oral small molecule inhibitor that selectively targets vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR1/2/3), thereby inhibiting tumor angiogenesis. Tislelizumab is a humanized IgG4 monoclonal antibody that binds to programmed cell death protein 1 (PD‑1), blocking its interaction with PD-L1 and PD-L2 to enhance antitumor immune responses. The combination aims to provide synergistic antitumor effects by simultaneously targeting tumor cells directly, disrupting their blood supply, and enhancing immune-mediated killing.